Business Description
Zymeworks Inc
NAICS : 325412
SIC : 2836
ISIN : US98985Y1082
Share Class Description:
FRA:ZA8: Registered ShsDescription
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.68 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.02 | |||||
| Beneish M-Score | -2.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year EBITDA Growth Rate | 20.7 | |||||
| 3-Year EPS without NRI Growth Rate | 22.1 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -9.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 25.82 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.65 | |||||
| 9-Day RSI | 35.57 | |||||
| 14-Day RSI | 41.61 | |||||
| 3-1 Month Momentum % | 9.17 | |||||
| 6-1 Month Momentum % | 46.01 | |||||
| 12-1 Month Momentum % | 42.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | |||||
| Quick Ratio | 4.1 | |||||
| Cash Ratio | 3.54 | |||||
| Days Sales Outstanding | 203.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 | |||||
| Shareholder Yield % | 0.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -194.65 | |||||
| Net Margin % | -182.75 | |||||
| FCF Margin % | -95.55 | |||||
| ROE % | -27.06 | |||||
| ROA % | -21.1 | |||||
| ROIC % | -66.43 | |||||
| 3-Year ROIIC % | 101.42 | |||||
| ROC (Joel Greenblatt) % | -309.69 | |||||
| ROCE % | -25.55 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.15 | |||||
| PB Ratio | 2.39 | |||||
| Price-to-Tangible-Book | 2.3 | |||||
| EV-to-EBIT | -4.88 | |||||
| EV-to-EBITDA | -5.36 | |||||
| EV-to-Revenue | 9.51 | |||||
| EV-to-Forward-Revenue | 8.22 | |||||
| EV-to-FCF | -10.02 | |||||
| Price-to-GF-Value | 0.95 | |||||
| Price-to-Net-Current-Asset-Value | 3.59 | |||||
| Price-to-Net-Cash | 4.53 | |||||
| Earnings Yield (Greenblatt) % | -20.48 | |||||
| FCF Yield % | -6.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zymeworks Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 57.042 | ||
| EPS (TTM) (€) | -1.366 | ||
| Beta | 1.15 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.22 | ||
| Volatility % | 50.77 | ||
| 14-Day RSI | 41.61 | ||
| 14-Day ATR (€) | 0.460358 | ||
| 20-Day SMA (€) | 12.795 | ||
| 12-1 Month Momentum % | 42.28 | ||
| 52-Week Range (€) | 7.4 - 14.8 | ||
| Shares Outstanding (Mil) | 68.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zymeworks Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zymeworks Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zymeworks Inc Frequently Asked Questions
What is Zymeworks Inc(FRA:ZA8)'s stock price today?
The current price of FRA:ZA8 is €11.60. The 52 week high of FRA:ZA8 is €14.80 and 52 week low is €7.40.
When is next earnings date of Zymeworks Inc(FRA:ZA8)?
The next earnings date of Zymeworks Inc(FRA:ZA8) is 2025-03-06 Est..
Does Zymeworks Inc(FRA:ZA8) pay dividends? If so, how much?
Zymeworks Inc(FRA:ZA8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers